Revalesio Corp is a clinical-stage pharmaceutical company based in Fife, WA, dedicated to developing safe and effective treatments for neurological diseases. Their pioneering science and nanotechnology approach target fundamental disease mechanisms, such as mitochondrial dysfunction and inflammation, to provide neuroprotection, slow disease progression, and enhance the quality of life for patients.
With a unique nanotechnology platform, Revalesio Corp creates a new class of drugs that leverage physics to address neuronal imbalances. Their promising pipeline includes RNS60, a lead candidate rapidly advancing in clinical programs for amyotrophic lateral sclerosis (ALS) and ischemic stroke. Through their innovative research and commitment to improving millions of lives, Revalesio Corp is at the forefront of restoring hope for patients with neurodegenerative diseases.
Generated from the website